Ganga Pharmaceuticals Reports Net Profit of Rs 2.48 Lakhs for Half-Year Ended September 2025

Ganga Pharmaceuticals Limited announced its unaudited financial results for the half-year ended September 30, 2025. The company reported revenue from operations of Rs 136.65 lakhs compared to Rs 263.74 lakhs in the previous year. Net profit for the period was Rs 2.48 lakhs versus Rs 7.90 lakhs in the corresponding previous period. Basic earnings per share stood at Rs 0.08 compared to Rs 0.16 in the previous year. During the reporting period, the company converted 10,75,000 warrants into equity shares, raising Rs 112.88 lakhs. The paid-up equity share capital increased to Rs 5,91,15,000 following the conversion. Out of the funds raised, Rs 53.48 lakhs has been utilized for stated purposes with the balance kept in bank accounts. The remaining 7,00,000 warrants were forfeited as warrant holders did not remit the balance consideration within the prescribed time.

Plutus Capital Management Acquires 7.75% Stake in Ganga Pharmaceuticals Through Warrant Conversion

Plutus Capital Management LLP acquired 375,000 shares in Ganga Pharmaceuticals Ltd, representing a 7.75% stake in the company. The acquisition occurred through the conversion of convertible warrants into equity shares on July 17, 2025. Prior to this transaction, Plutus Capital held no shares in the company. The acquisition increased Ganga Pharmaceuticals' total equity share capital from Rs. 4.84 crore to Rs. 5.91 crore, with the total number of equity shares rising from 48.37 lakh to 59.12 lakh shares of Rs. 10 each. Plutus Capital Management is not part of the promoter group. The company's shares are listed on BSE Limited under scrip code 539680.

Plutus Capital Management Acquires 7.75% Stake in Ganga Pharmaceuticals Through Warrant Conversion

Plutus Capital Management LLP acquired a 7.75% stake in Ganga Pharmaceuticals Ltd by purchasing 3,75,000 shares through the conversion of convertible warrants. The acquisition was completed through preferential allotment on July 17, 2025. Prior to this transaction, Plutus Capital held no shares in the company. The acquisition increased Ganga Pharmaceuticals' equity share capital from Rs. 4,83,65,000 (48,36,500 shares) to Rs. 5,91,15,000 (59,11,500 shares). Plutus Capital Management is not part of the promoter group. The company's shares are listed on BSE Limited.

Ganga Pharmaceuticals Allots 3 Lakh Warrants to Promoters Through Preferential Allotment

Ganga Pharmaceuticals Limited allotted 3,00,000 warrants convertible into equivalent equity shares to promoters and promoter group on July 17, 2025. The warrants have a face value of Rs. 10 each and were issued through preferential allotment. The acquirers include Srijana Bharat Sharma (promoter) who received 2,00,000 warrants and Anagh Bharat Sharma (promoter group) who received 1,00,000 warrants. Following this acquisition, the promoter and promoter group's total holding increased to 30,09,550 shares, representing 50.91% of the company's equity. The company's equity share capital increased from Rs. 4,83,65,000 to Rs. 5,91,15,000 after the allotment. The company's shares are listed on BSE Limited.